| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Contents
|
|
|
2012
|
17 |
1-2 |
p. iii-
1 p.
|
artikel
|
| 2 |
Contents
|
|
|
2012
|
17 |
1-2 |
p. i-
1 p.
|
artikel
|
| 3 |
Curcumin nanoformulations: a future nanomedicine for cancer
|
Yallapu, Murali M.
|
|
2012
|
17 |
1-2 |
p. 71-80
10 p.
|
artikel
|
| 4 |
HIV-1 proteins join the family of LIM kinase partners. New roads open up for HIV-1 treatment
|
Manetti, Fabrizio
|
|
2012
|
17 |
1-2 |
p. 81-88
8 p.
|
artikel
|
| 5 |
Hypothesis driven drug design: improving quality and effectiveness of the design-make-test-analyse cycle
|
Plowright, Alleyn T.
|
|
2012
|
17 |
1-2 |
p. 56-62
7 p.
|
artikel
|
| 6 |
Metabolomics and cancer drug discovery: let the cells do the talking
|
D’Alessandro, Angelo
|
|
2012
|
17 |
1-2 |
p. 3-9
7 p.
|
artikel
|
| 7 |
Patents discipline is key to securing big pharma investment
|
Jones, Nicholas
|
|
2012
|
17 |
1-2 |
p. 1-2
2 p.
|
artikel
|
| 8 |
Target–drug interactions: first principles and their application to drug discovery
|
Núñez, Sara
|
|
2012
|
17 |
1-2 |
p. 10-22
13 p.
|
artikel
|
| 9 |
Targeting heat shock response pathways to treat pancreatic cancer
|
Xia, Yi
|
|
2012
|
17 |
1-2 |
p. 35-43
9 p.
|
artikel
|
| 10 |
The potential of incretin-based therapies in type 1 diabetes
|
Suen, Chen S.
|
|
2012
|
17 |
1-2 |
p. 89-95
7 p.
|
artikel
|
| 11 |
The regulatory framework of biosimilars in the European Union
|
Minghetti, Paola
|
|
2012
|
17 |
1-2 |
p. 63-70
8 p.
|
artikel
|
| 12 |
The role of fragment-based and computational methods in polypharmacology
|
Bottegoni, Giovanni
|
|
2012
|
17 |
1-2 |
p. 23-34
12 p.
|
artikel
|
| 13 |
Toward in silico structure-based ADMET prediction in drug discovery
|
Moroy, Gautier
|
|
2012
|
17 |
1-2 |
p. 44-55
12 p.
|
artikel
|
Tijdschrift beschrijving